Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4

FEBS Letters

Volumn 527, Issue 1-3, 2002, Pages 255-262

  Hatse, Sigrid ^a   Princen, Katrien ^a   Bridger, Gary ^b   De Clercq, Erik ^a   Schols, Dominique ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b GENZYME CORPORATION   (United States)

Author keywords

Bicyclam; Calcium signaling; Chemokine receptor antagonist; Chemotaxis; CXCR4

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; GENTAMICIN; PHORBOL ESTER; PUROMYCIN; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

AGONIST; AMINO ACID SEQUENCE; ARTICLE; ASTHMA; ATHEROSCLEROSIS; BREAST CANCER; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CELL TYPE; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; ENDOCYTOSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INHIBITION KINETICS; METASTASIS; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN INTERACTION; RHEUMATOID ARTHRITIS;

ANTI-HIV AGENTS; CALCIUM; CELL MOVEMENT; CELLS, CULTURED; CHEMOKINES, CXC; CHEMOTAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCYTOSIS; HETEROCYCLIC COMPOUNDS; HUMANS; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4; TETRADECANOYLPHORBOL ACETATE;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0037063329     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-5793(02)03143-5     Document Type: Article

References (31)

1. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., Miller L.H., Oppenheim J.J., Power C.A. Pharmacol. Rev. 52:2000;145-176.
2. Thelen M. Nat. Immunol. 2:2001;129-134.
3. Baggiolini M. Nature. 392:1998;565-568.
4. Gerard C., Rollins B.J. Nat. Immunol. 2:2001;108-115.
5. Murdoch C., Finn A. Blood. 95:2000;3032-3043.
6. Premack B.A., Schall T.J. Nat. Med. 2:1996;1174-1178.
7. Rossi D., Zlotnik A. Annu. Rev. Immunol. 18:2000;217-242.
8. Balkwill F., Mantovani A. Lancet. 357:2001;539-545.
9. Gonzalo J.A., Lloyd C.M., Peled A., Delaney T., Coyle A.J., Gutierrez-Ramos J.C. J. Immunol. 165:2000;499-508.
10. Nanki T., Hayashida K., El-Gabalawy H.S., Suson S., Shi K., Girschick H.J., Yavuz S., Lipsky P.E. J. Immunol. 165:2000;6590-6598.
11. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Nature. 410:2001;50-56.
12. Alkhatib G., Combadiere C., Broder C.C., Feng Y., Kennedy P.E., Murphy P.M., Berger E.A. Science. 272:1996;1955-1958.
13. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. Science. 272:1996;872-877.
14. De Clercq E., Yamamoto N., Pauwels R., Balzarini J., Witvrouw M., De Vreese K., Debyser Z., Rosenwirth B., Peichl P., Datema R., Thornton D., Skerlj R.T., Gaul F., Padmanabhan S., Bridger G., Henson G., Abrams M.J. Antimicrob. Agents Chemother. 38:1994;668-674.
15. De Vreese K., Reymen D., Griffin P., Steinkasserer A., Werner G., Bridger G.J., Este J., James W., Henson G.W., Desmyter J., Anne J., De Clercq E. Antiviral Res. 29:1996;209-219.
16. Schols D., Struyf S., Van Damme J., Este J.A., Henson G., De Clercq E. J. Exp. Med. 186:1997;1383-1388.
17. Donzella G.A., Schols D., Lin S.W., Este J.A., Nagashima K.A., Maddon P.J., Allaway G.P., Sakmar T.P., Henson G., De Clercq E., Moore J.P. Nat. Med. 4:1998;72-77.
18. Matthys P., Hatse S., Vermeire K., Wuyts A., Bridger G., Henson G.W., De Clercq E., Billiau A., Schols D. J. Immunol. 167:2001;4686-4692.
19. Bridger G.J., Skerlj R.T., Thornton D., Padmanabhan S., Martellucci S.A., Henson G.W., Abrams M.J., Yamamoto N., De Vreese K., Pauwels R., et al. J. Med. Chem. 38:1995;366-378.
20. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., Springer T.A. Nature. 382:1996;829-833.
21. Oberlin E., Amara A., Bachelerie F., Bessia C., Virelizier J.L., Arenzana-Seisdedos F., Schwartz O., Heard J.M., Clark-Lewis I., Legler D.F., Loetscher M., Baggiolini M., Moser B. Nature. 382:1996;833-835.
22. Labrosse B., Brelot A., Heveker N., Sol N., Schols D., De Clercq E., Alizon M. J. Virol. 72:1998;6381-6388.
23. Zhang Y., Lou B., Lal R.B., Gettie A., Marx P.A., Moore J.P. J. Virol. 74:2000;6893-6910.
24. Signoret N., Oldridge J., Pelchen-Matthews A., Klasse P.J., Tran T., Brass L.F., Rosenkilde M.M., Schwartz T.W., Holmes W., Dallas W., Luther M.A., Wells T.N., Hoxie J.A., Marsh M. J. Cell Biol. 139:1997;651-664.
25. Gerlach L.O., Skerlj R.T., Bridger G.J., Schwartz T.W. J. Biol. Chem. 276:2001;14153-14160.
26. Hatse S., Princen K., Gerlach L.O., Bridger G., Henson G., De Clercq E., Schwartz T.W., Schols D. Mol. Pharmacol. 60:2001;164-173.
27. Egberink H.F., De Clercq E., Van Vliet A.L., Balzarini J., Bridger G.J., Henson G., Horzinek M.C., Schols D. J. Virol. 73:1999;6346-6352.
28. Hendrix C.W., Flexner C., MacFarland R.T., Giandomenico C., Fuchs E.J., Redpath E., Bridger G., Henson G.W. Antimicrob. Agents Chemother. 44:2000;1667-1673.
29. Schols, D., Claes, S., De Clercq, E., Hendrix, C., Bridger, G., Calandra, G., Henson, G.W., Fransen, S., Huang, W., Whitcomb, J.M., Petropoulos, C.J., AMD3100 HIV Study Group (2002) in: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, pp. 53.
30. Abi-Younes S., Sauty A., Mach F., Sukhova G.K., Libby P., Luster A.D. Circ. Res. 86:2000;131-138.
31. Lukacs N.W., Berlin A., Schols D., Skerlj R.T., Bridger G.J. Am. J. Pathol. 160:2002;1353-1360.